Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers

Women with advanced stage ovarian cancer (OC) have a five-year survival rate of less than 25%. OC progression is associated with accumulation of epigenetic alterations and aberrant DNA methylation in gene promoters acts as an inactivating “hit” during OC initiation and progression. Abnormal DNA methylation in OC has been used to predict disease outcome and therapy response. To globally examine DNA methylation in OC, we used next-generation sequencing technology, MethylCap-sequencing, to screen 75 malignant and 26 normal or benign ovarian tissues. Differential DNA methylation regions (DMRs) were identified, and the Kaplan–Meier method and Cox proportional hazard model were used to correlate methylation with clinical endpoints. Functional role of specific genes identified by MethylCap-sequencing was examined in in vitro assays. We identified 577 DMRs that distinguished (p < 0.001) malignant from non-malignant ovarian tissues; of these, 63 DMRs correlated (p < 0.001) with poor progression free survival (PFS). Concordant hypermethylation and corresponding gene silencing of sonic hedgehog pathway members ZIC1 and ZIC4 in OC tumors was confirmed in a panel of OC cell lines, and ZIC1 and ZIC4 repression correlated with increased proliferation, migration and invasion. ZIC1 promoter hypermethylation correlated (p < 0.01) with poor PFS. In summary, we identified functional DNA methylation biomarkers significantly associated with clinical outcome in OC and suggest our comprehensive methylome analysis has significant translational potential for guiding the design of future clinical investigations targeting the OC epigenome. Methylation of ZIC1, a putative tumor suppressor, may be a novel determinant of OC outcome.

[1]  D. Matei,et al.  Minireview: epigenetic changes in ovarian cancer. , 2009, Endocrinology.

[2]  Susan J Clark,et al.  DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. , 2008, Gynecologic oncology.

[3]  Zachary C. Dobbin,et al.  Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer , 2012, Molecular Cancer Therapeutics.

[4]  R. Bast,et al.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.

[5]  S. Inoue,et al.  Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  Lixin Wei,et al.  CpG island methylator phenotype of cell-cycle regulators associated with TNM stage and poor prognosis in patients with oesophageal squamous cell carcinoma , 2010, Journal of Clinical Pathology.

[7]  Pearlly Yan,et al.  Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer , 2005, Molecular Cancer Therapeutics.

[8]  Paul Cairns,et al.  Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients , 2004, Cancer Research.

[9]  J. Issa.  Methylation and prognosis: of molecular clocks and hypermethylator phenotypes. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  Jacqueline A. Hall,et al.  CpG island methylation of DNA damage response genes in advanced ovarian cancer. , 2005, Cancer research.

[11]  E. Wang,et al.  Role of Hedgehog Signaling in Ovarian Cancer , 2008, Clinical Cancer Research.

[12]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[13]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[14]  A. Kaneda,et al.  CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. , 2005, Cancer research.

[15]  H. Su,et al.  Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway , 2010, International journal of cancer.

[16]  I. Meinhold-Heerlein,et al.  Progression-Free Survival in Ovarian Cancer Is Reflected in Epigenetic DNA Methylation Profiles , 2011, Oncology.

[17]  Robert Brown,et al.  Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. , 2001, The American journal of pathology.

[18]  R. Ozols,et al.  The management of recurrent ovarian cancer. , 2007, Seminars in oncology.

[19]  D. Katsaros,et al.  The Zinc Finger Gene ZIC2 Has Features of an Oncogene and Its Overexpression Correlates Strongly with the Clinical Course of Epithelial Ovarian Cancer , 2012, Clinical Cancer Research.

[20]  N. Hacker,et al.  Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers. , 2012, Cancer letters.

[21]  L. Hartmann,et al.  Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. , 2001, Cancer research.

[22]  K. Nephew,et al.  DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. , 2001, Gynecologic oncology.

[23]  Dong-hong Zhang,et al.  Status and Significance of CpG Island Methylator Phenotype in Endometrial Cancer , 2011, Gynecologic and Obstetric Investigation.

[24]  E. Reed,et al.  Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum–DNA adduct repair , 2012, Oncogene.

[25]  T. Beißbarth,et al.  CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer. , 2012, Surgery.

[26]  Jun Yu,et al.  Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer , 2008, British Journal of Cancer.

[27]  K J Millen,et al.  The ZIC gene family in development and disease , 2005, Clinical genetics.

[28]  R. Arceci.  CpG Island Methylator Phenotype Is a Strong Determinant of Poor Prognosis in NeuroblastomasAbe M, Ohira M, Kaneda A, et al (Natl Cancer Ctr Research Inst, Tokyo; Univ of Tokyo; Chiba Cancer Ctr Research Inst, Japan) Cancer Res 65:828-834, 2005§ , 2006 .

[29]  J. Ajani,et al.  Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  Barbara Stecca,et al.  The Gli code: an information nexus regulating cell fate, stemness and cancer. , 2007, Trends in cell biology.

[31]  M. Ehrlich,et al.  DNA methylation in cancer: too much, but also too little , 2002, Oncogene.

[32]  Constanze Zeller,et al.  Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free Survival , 2011, Clinical Cancer Research.

[33]  K. Mikoshiba,et al.  Molecular Properties of Zic Proteins as Transcriptional Regulators and Their Relationship to GLI Proteins* , 2001, The Journal of Biological Chemistry.

[34]  George S Watts,et al.  DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage , 2008, BMC Medical Genomics.

[35]  L. Elnitski,et al.  Differential Analysis of Ovarian and Endometrial Cancers Identifies a Methylator Phenotype , 2012, PloS one.

[36]  Jun Yu,et al.  ZIC1 Is Downregulated through Promoter Hypermethylation, and Functions as a Tumor Suppressor Gene in Colorectal Cancer , 2011, PloS one.

[37]  Ching‐Ming Liu.  Cancer of the ovary. , 2005, The New England journal of medicine.

[38]  F. Chan,et al.  ZIC1 is downregulated through promoter hypermethylation in gastric cancer. , 2009, Biochemical and biophysical research communications.

[39]  P. Ip,et al.  Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation , 2008, Carcinogenesis.

[40]  Meng Li,et al.  Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer , 2009, BMC Medical Genomics.

[41]  Sandya Liyanarachchi,et al.  Prognostic DNA Methylation Biomarkers in Ovarian Cancer , 2006, Clinical Cancer Research.

[42]  Tim Hui-Ming Huang,et al.  Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  Lin Zhao,et al.  Clinicopathological Significance and Prognostic Value of DNA Methyltransferase 1, 3a, and 3b Expressions in Sporadic Epithelial Ovarian Cancer , 2012, PloS one.

[44]  M. Parmar,et al.  First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence , 2002, British Journal of Cancer.

[45]  P. Catalano,et al.  Association between DNA Methylation and Shortened Survival in Patients with Advanced Colorectal Cancer Treated with 5-Fluorouracil–Based Chemotherapy , 2007, Clinical Cancer Research.

[46]  Robert Brown,et al.  Hypermethylation of 18S and 28S Ribosomal DNAs Predicts Progression-Free Survival in Patients with Ovarian Cancer , 2005, Clinical Cancer Research.

[47]  M. Widschwendter,et al.  Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers. , 2010, Epigenomics.

[48]  Martin Widschwendter,et al.  HOXA11 DNA methylation—A novel prognostic biomarker in ovarian cancer , 2008, International journal of cancer.

[49]  K. Mikoshiba,et al.  Physical and Functional Interactions between Zic and Gli Proteins* , 2001, The Journal of Biological Chemistry.

[50]  I. Thompson,et al.  Epigenetic deregulation of the anaplastic lymphoma kinase gene modulates mesenchymal characteristics of oral squamous cell carcinomas. , 2013, Carcinogenesis.

[51]  S. Baylin,et al.  Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. , 1999, Cancer research.

[52]  J. Minna,et al.  Promoter Hypermethylation Profile of Ovarian Epithelial Neoplasms , 2005, Clinical Cancer Research.

[53]  R H Hruban,et al.  Hypermethylation of multiple genes in pancreatic adenocarcinoma. , 2000, Cancer research.

[54]  Lee L. Rubin,et al.  Targeting the Hedgehog pathway in cancer , 2006, Nature Reviews Drug Discovery.